Chudwin D S, Wara D W, Matthay K K, Caulfield M H, Schiffmann G, Mentzer W C, Ammann A J
J Pediatr. 1983 Jan;102(1):51-4. doi: 10.1016/s0022-3476(83)80285-6.
Opsonic defects have been reported in unimmunized patients with sickle cell disease. We found significant increases (P less than 0.001) in serum opsonic activity, measured by a radiolabeled bacterial uptake assay, and in type 7 pneumococcal polysaccharide antibody concentration in 17 such patients 2 years of age or older after pneumococcal polysaccharide immunization. All 17 patients and six healthy controls achieved a type 7 antibody concentration of more than 300 ng antibody nitrogen per milliliter, believed to be the protective level of antibody in vivo. Six patients with sickle cell disease less than 2 years of age did not have a significant increase in type 7 antibody concentration after immunization. Only three of these six patients achieved a postimmunization type 7 antibody concentration exceeding 300 ng Ab N/ml. Overall, 16 of 23 patients with sickle cell disease (70%) had a twofold or greater increase in type 7 antibody concentration, and 13 of these (81%) had a corresponding increase in opsonic activity (P less than 0.001). Thus most patients who responded to pneumococcal polysaccharide immunization had a concurrent increase in opsonic activity in vitro.
据报道，未免疫的镰状细胞病患者存在调理素缺陷。我们发现，通过放射性标记细菌摄取试验测定，17例2岁及以上的此类患者在接种肺炎球菌多糖疫苗后，血清调理活性显著增加（P小于0.001），7型肺炎球菌多糖抗体浓度也显著增加。所有17例患者和6名健康对照者的7型抗体浓度均达到每毫升300纳克抗体氮以上，这被认为是体内抗体的保护水平。6例2岁以下的镰状细胞病患者在免疫后7型抗体浓度没有显著增加。这6例患者中只有3例免疫后7型抗体浓度超过300纳克抗体氮/毫升。总体而言，23例镰状细胞病患者中有16例（70%）的7型抗体浓度增加了两倍或更多，其中13例（81%）的调理活性相应增加（P小于0.001）。因此，大多数对肺炎球菌多糖免疫有反应的患者在体外同时出现调理活性增加。
